Henning is a senior executive and entrepreneur with more than 25 years of operational experience in Pharma, Biotech, Venture capital and Private Equity. Henning co-founded Lario Therapeutics in Nov 2021 and is leading the company as CEO. He is also co-founder and CEO of Epidarex Exeed, the therapeutic engine of Epidarex and acting as Venture Partner at Epidarex Capital.

Henning currently serves on the Board of Directors of Lario Therapeutics Ltd, Epidarex Exeed Ltd as well as Upperton Limited. In addition, he is member of the Heath Care Advisory Board at Inflexion.

Previously, Henning served as President R&D at Aptuit, a leading R&D organization. As a member of the executive team he led the growth and transformation including a successful exit. Prior to that he acted as SVP and Head of Global Drug Discovery at Grünenthal and held senior roles at Sanofi-Aventis and Bayer Pharma.

In 2018 Henning earned an executive MBA degree from the IMD in Lausanne. He holds a PhD in Chemistry with an additional degree in Molecular Genetics. Henning worked with Nobel laureate Prof. E.J. Corey at Harvard.